Cardiovascular and Safety Signals After GLP‑1 Discontinuation: Register Evidence

A large register-based analysis of U.S. veterans with type 2 diabetes reported that stopping or interrupting GLP-1 receptor agonist therapy was associated with higher rates of major adverse cardiovascular events than continuing treatment. Treatment status was assessed in six-month intervals, allowing comparisons between continuous use and periods when therapy was interrupted or discontinued. The report describes these outcomes as being “linked to” differences in risk between continued use and treatment gaps.

The cohort included 333,687 U.S. veterans with type 2 diabetes, and outcomes among those prescribed GLP-1 receptor agonists were compared with outcomes among those prescribed sulfonylureas. Participants were followed for up to three years, with repeated six-month assessments used to categorize treatment patterns over time. The composite outcome was described as heart attack, stroke, and death, with reporting focused on how that composite varied across exposure patterns.

For continuous GLP-1 use, the report described fewer major adverse cardiovascular events than with sulfonylureas at three years, estimated as an 18% relative reduction and framed as roughly 4 fewer events per 100 people over three years. In the same account, people who used GLP-1 therapy for less than 18 months before discontinuing were reported not to have a significant risk reduction by the end of follow-up compared with the sulfonylurea group. The narrative linked the apparent advantage to persistence on therapy rather than brief exposure. Duration of continuous use was treated as a central element of the reported association.

The timing of interruptions and discontinuation was also described as important, with treatment interruptions of about six months before resuming associated with reduced benefit relative to staying on therapy. Longer periods off therapy were reported to correspond to progressively higher risk, including a 14% increased risk after one year off and up to a 22% increased risk after two years off, compared with continued use. The reportalso stated that resumption was associated with a smaller net benefit than continuous therapy, even when participants restarted before the end of follow-up. Across this framing, more time off medication was described as tracking with greater erosion of the observed cardiovascular advantage.

The authors noted that stopping GLP‑1 receptor agonists was characterized as producing “metabolic reversal,” described as a resurgence in inflammation, blood pressure, and cholesterol, alongside the return of weight. Restarting therapy restored some protection but did not return benefits to prior levels.